Literature DB >> 18007155

Preclinical safety evaluation of Gd-EOB-DTPA (Primovist).

Olaf Döhr1, Rainer Hofmeister, Marianne Treher, Hermann Schweinfurth.   

Abstract

OBJECTIVES: Gadoxetic acid [gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid (Gd-EOB-DTPA); Primovist] is a liver specific contrast agent for magnetic resonance imaging. For risk assessment of the single diagnostic use the toxicity of this compound was assessed.
MATERIALS AND METHODS: Studies into acute, repeated-dose, reproductive and developmental toxicity, and local tolerance, contact sensitizing, and genotoxic potential were performed.
RESULTS: Lethality was observed after a single intravenous administration at doses 2 orders of magnitude higher than the clinical dose. The no observed adverse effect levels after repeated administration markedly exceeds the single diagnostic dose in humans and no unexpected organ toxicity was observed. No indications of reproductive and developmental toxicity, potential contact allergenic, and genotoxic effects were observed. Gd-EOB-DTPA was well tolerated after intravenous administration.
CONCLUSIONS: Gd-EOB-DTPA was well tolerated with high safety margins between the single diagnostic dose and the doses showing adverse effects in animal studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18007155     DOI: 10.1097/RLI.0b013e318137a471

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  6 in total

1.  Biliary reflux detection in anomalous union of the pancreatico-biliary duct patients.

Authors:  Suk Keu Yeom; Seung Wha Lee; Sang Hoon Cha; Hwan Hoon Chung; Bo Kyung Je; Baek Hyun Kim; Jong Jin Hyun
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  Usefulness of two-point Dixon fat-water separation technique in gadoxetic acid-enhanced liver magnetic resonance imaging.

Authors:  Ying Ding; Sheng-Xiang Rao; Cai-Zhong Chen; Ren-Chen Li; Meng-Su Zeng
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

3.  Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.

Authors:  Jean-Nicolas Vauthey; Elijah Dixon; Eddie K Abdalla; W Scott Helton; Timothy M Pawlik; Bachir Taouli; Antoine Brouquet; Reid B Adams
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

4.  A Hyaluronic Acid-Conjugated Gadolinium Hepatocyte-Specific T1 Contrast Agent for Liver Magnetic Resonance Imaging.

Authors:  MyeongJu Moon; Reju George Thomas; Seon-U Heo; Myong-Suk Park; Woo Kyun Bae; Suk Hee Heo; Nam Yeol Yim; Yong Yeon Jeong
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

5.  The role of MRI using liver-specific contrast agent in the assessment of focal liver lesion.

Authors:  Giuseppe D'Ippolito
Journal:  Radiol Bras       Date:  2014 Sep-Oct

Review 6.  Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.

Authors:  Julie Davies; Petra Siebenhandl-Wolff; Francois Tranquart; Paul Jones; Paul Evans
Journal:  Arch Toxicol       Date:  2022-01-08       Impact factor: 5.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.